In 1969, fifty years ago, a young professor of ceramic engineering created a 4-component glass to be used as a bone replacement material. That material became known as "Bioglass" and more generally as a class of materials known as bioactive glass. Those first experiments conducted by Dr. Larry Hench completely shifted the paradigm of how the biomaterials and medical communities look at the interactions between inorganic materials and tissues in the body. This article will touch on just a few highlights of the development of bioactive glasses and relate those to the concepts of bioactivity and tissue bonding.
The early years
The story about how Professor Hench came to be inspired to switch his focus from researching radiation damage in glass for space-based applications and the dielectric properties of glass and glass-ceramics to biomaterials has been told in numerous publications, so those details won't be repeated here. Perhaps the best and most interesting account is Dr. Hench's article in 2006, "The story of Bioglass", and it is worth reading to gain an overview of some of the details of the development of this class of biomaterials [1] . While the invention of bioactive glass has resulted in significant commercial success in some applications, what is salient and perhaps most important is how that invention and the unique surface properties of a limited series of glass compositions has created an entire field of study; namely bioactive materials.
At the time that Professor Hench created the first bioactive glass compositions, the majority of research was based *Corresponding Author: David Greenspan: Spinode Consulting St Augustine, United States of America; Email: dspinode@gmail.com in part on the theory that by making materials less reactive, the inflammatory response and hence 'rejection' of the implant material would be lessened, resulting in a more successful device. A survey of the literature at that time supports this point [2] [3] [4] [5] . In the late 1960's and early 1970's biomaterials research was focused on blood compatible surfaces, metals with minimal reactivity in the body, some ceramic bone graft materials and polymers that would not elicit an intense inflammatory response, but there was no concept about material-tissue bonding. It was beyond the realm of possibility at that time that a synthetic material could have a positive impact on tissue healing (later expanded to tissue regeneration) and have an ability to form a bond with the repairing tissue.
The first studies conducted by Professor Hench were all directed towards repair of bone tissue since that was an area within the medical device community that was growing rapidly. The initial publications of the results of those early experiments with Bioglass were initially met with some curiosity and even skepticism in the early 1970's. While those early publications from Professor Hench's group verified that some kind of direct attachment between bone and the glass implant had occurred, the mechanisms could not be easily explained and a rigorous theory about how this phenomenon took place had not yet been developed [6] [7] [8] [9] .
During the early years of development of various bioactive glass and glass-ceramic materials, Professor Hench published a number of articles on the surface reactions of these bioactive glasses. Many of the salient publications are described in "The story of Bioglass" by Hench, referenced above. The observations of the interface between tissue and material in simple monolithic bone implants in either rats or rabbits were then compared with the in vitro data to gain a better understanding of the reactions and sequence of those reactions leading to this bonding interface. Much of the detail of these early works are captured in a series of 9 reports to the U.S. Army Medical Research and Development Command which funded the initial work and continued to fund Professor Hench's program for 9 years [9] . While it is beyond the scope of this article to go into details of those early works, it is interesting to note that the first compositions tested included crystallized compositions, including the original '45S5' (45 wt% SiO2, 24.5 wt% Na2O, 24.5 wt% CaO and 6 wt% P 2 O 5 ) composition as a glass-ceramic. The hypothesis was that a glass-ceramic material would have the mechanical strength to support load bearing applications. Once the chemical bond with bone was demonstrated in those first studies it was further postulated the crystalline structure of the glass-ceramic, coupled with the surface reactivity of the glass-ceramic enhanced and was responsible for the precipitation of the calcium phosphate layer [10] .
When scanning the literature today, the original, iconic '45S5' composition is still often referenced. What has been lost to much of the history is that the first 4 to 5 years of research looked at a wide range of silicate compositions, including, different levels of silica as the network former, additions of boron and fluoride to modify melting temperature for flame spraying coatings, as well as the comparison of amorphous versus crystallized compositions [9, 10] . Because these U.S. Army Reports were not widely circulated, nor peer-reviewed, much of that early work that helped shape the direction of research with bioactive glass and theory of bone bonding has never been seen by the biomaterials community.
However, as more researchers began to study these materials, by 1980 there was a slow acceptance by the biomaterials community of the premise that an inorganic, synthetic material could directly attach to bone tissue without an interposing fibrous layer. This acceptance led researchers to look at a wide range of materials that might bond to bone.
Bioglass, surface reactivity and the term "bioactivity"
The first use of the term "bioglass" occurs in the second U.S. Army Report. That term appears in the summary of accomplishments and the exact term was written as "bioglass-ceramic" [10] . It is important to note that the first use of this word included the term "ceramic". The initial thrust of Professor Hench's research was to use a glass-ceramic material for bone replacement as he believed that these crystallized compositions would be strong enough to be load bearing, so many of the early peer reviewed publications were of Bioglass-ceramic constructs as well as amorphous glass samples. Over the next few years, the term became used more frequently for both amorphous and crystalline compositions, and in 1976 the word "Bioglass " was actually trademarked by the University of Florida.
It is not clear when the first use of the term 'bioactive glass' appeared in the literature, or the term 'bioactivity', but by 1982, in a publication by Hulbert, Hench, Forbers and Bowman, a definition for a 'bioactive material' appeared. The definition is as follows: "A bioactive material is one that elicits a specific biological response at the interface of the material that results in the formation of a bond between tissues and the material" [11] . In time, this definition became the definition of 'bioactivity' as it relates to glass and other biomaterials used as implant materials.
In 1976, a publication by Clark, Hench and Paschall described the multi-layer interfacial zones that form between the original glass surface and bone tissue [12] . In this publication, the authors laid out the basic sequence of events that occur following implantation, based on both in vivo histological results and in vitro reaction studies of multiple glass compositions. The authors describe a dynamic surface chemistry that is dependent on glass composition in both hard and soft tissue. This was the first attempt to create a fully operational theory of the mechanism of tissue bonding. As interest in the concept of bone-bonding and tissue attachment grew through the late 1970's and into the early 1980's, the pace of research in the biomaterials community quickened. Research efforts included new compositions of glass, new applications and a more in-depth understanding about how the reactivity of these materials affected their performance. In fact, the basic premises laid out in that 1976 publication were validated through the research of investigators around the world who were looking at a myriad of new biomaterials.
Following from the theory of the influence of surface chemistry of bioactive glass on the interface with bone, Professor Hench continued to refine his approach and by the early 1980's had published the now well accepted and often used 'reaction sequence' that occurs when bioactive glass is implanted in bone or soft tissue. While there are many different forms of this figure that have been published, Figure 1 represents the first steps in the reaction sequence that leads to the formation of a crystalline hydroxyl carbonate apatite (HCA) layer. This layer was described as the bonding layer; Hench stated that for a bond with tissue to occur a layer of biologically active HCA must form [13] . This theory was tested often and by many researchers, and by 1990 this was accepted by most as the mechanism of bone bonding [14] .
Today, one of the first attributes to be tested for new bioactive materials, or modifications of existing materials is whether an HCA layer will form on the surface. In fact, in many publications, the formation of an HCA layer is used as a surrogate for making the claim that a material is bioactive. The biomaterials community has promulgated, through the International Organization for Standardization (ISO), a standard in vitro test method determining the apatite forming ability of an implant material (ISO 22317) [15] . In this test method there is a description and definition of bioactivity, and although the standard does not purport to equate the HCA forming ability of a material to its bioactivity, that link is commonly made today. In fact, much of this linkage is owed to the often used and referenced compositional triangle of bioactive glass compositions and regions of both bone and soft tissue bonding produced by Professor Hench, and one such iteration is shown in Figure 2 . This diagram was created over a period of 10 to 15 years by adding data from numerous experiments, not only by Hench but many others as well [16] . In many descriptions of this figure, Hench describes the range of bioactivity of the various compositions within the different regions of that compositional triangle.
While Figure 1 lays out the reaction sequence as it is envisioned from mainly laboratory in vitro solution reac-tivity studies, what is missing from the reaction sequence is the fact that the organic elements in the body will start to react instantaneously with the surface of any material. Professor Hench updated this figure in the mid 1990's to include the biological events that occur at the surface of the glass, but these events still appear in the figure after the surface reactivity has resulted in the formation of an apatite layer [17] . Thus, while that diagram is a simple way of explaining how silicate bioactive glasses behave in solution, it does not at all convey a complete story of the behavior of these materials in vivo, nor does it explain the very positive attributes that these materials have shown in commercial use.
HCA layer and bioactivity: a result of surface reactivity or mechanism of tissue bonding?
While the concepts of bioactivity and tissue bonding and the HCA layer have become ubiquitous and accepted in the biomaterials community today, it is not clear that the story is that simple. In fact, a rabbit study published in 1997 showed that a bioactive glass particulate (45S5) implanted in the distal femur, produced bone regeneration of the defect much more rapidly and completely than a dense hydroxy apatite particulate [18] . From these results, it was clear to Professor Hench that the bone bonding and very rapid regeneration of tissue for the bioactive glass had to be at least partly due to the ionic release from the glass. This revelation set Professor Hench on to study how the ions released from bioactive glass affected osteoblasts and stem cells. In a series of publications beginning around 2000, Hench and others demonstrated that the stimulatory effect on bone cells was due, at least in part, to ions released from the glass [19] [20] [21] . In a number of these studies, the bioactive glass, usually the 45S5 composition, was reacted in cell culture medium, removed after a period of time, and that media replaced media in which various cell types were growing. Thus, a standard cell culture media was supplemented with ionic reaction products from the bioactive glass. In all cases, this additional ionic concentration led to stimulation of cellular activity. It was from these first studies that the conclusion was drawn that in addition to the HCA layer, the ionic release was critical to the stimulatory effect and rapid tissue repair ascribed to bioactive glasses. Today, researchers have determined that certain bioactive glasses can stimulate angiogenesis and that there is a dose response, suggesting that it is ionic release that is responsible for this effect. Day performed cell culture studies using a transwell system where bioactive glass particulates were exposed to the cell culture media, but not in contact with the cells [22] . A review of angiogenesis in bioactive glasses confirmed the effects both in vitro and in vivo [23] . These results confirmed the initial studies of this type performed by Professor Hench. Others have shown that bioactive glass possesses an anti-microbial activity, also ascribed to the release of ions from the glass [24, 25] . From these and other results it is not clear that one can simply draw a direct correlation between the formation of an HCA layer and the bioactivity of any bioactive glass.
Throughout this manuscript, the terms bioactive glass, bioactivity and bioglass have sometimes been used interchangeably. But 'bioactivity' is not solely related to this class of materials. Titanium implants, long a standard in dental implantology have always described their positive attributes with bone tissue as osseointegration. Osseointegration has been defined as the direct structural and functional connection between living bone and the surface of a load-bearing artificial implant [26] . Titanium alloys have also been long used in hip and knee prostheses as well as in other orthopedic hardware. In the late 1990's, titanium alloys were introduced as spinal fusion cages.
With the rapid growth of spinal fusion cages or spacers, a significant amount of research has been conducted on the osseointegration of these devices with bone. Researchers have shown that surface topography, namely multi-scale roughness has a positive effect on cellular attachment to the titanium alloy surface [27] [28] [29] . The realization that specific surface features can affect osseointegration and cellular behavior has allowed for major advances in the success of these implants. With these efforts more and more research publications have used the term 'bioactive' to describe the effect those surface features have on the osseointegration of the implant with bone as defined by Albrektsson [30, 31] .
If one takes Albrektssons' definition of osseointegration and Hench's definition of bioactivity one sees that these definitions as written are qualitative and not quantitative. Although Hench developed a system of classifying bioactive glass compositions with respect to whether they would bond with bone and soft tissue or just bone or not at all, these were limited to a range of silicate-based glasses. Greater bioactivity was ascribed to a material that produced more bone in a defect or that attached to certain types of soft tissue. There were also early attempts in some bone implant configurations to measure the strength of the bioactive glass-implant interface and compare that to the composition of the glass, although these efforts were not rigorous enough to be statistically definitive [32, 33] .
For the titanium dental implants however, the osseointegration could be measured by survivability of actual dental implants as a function of surface treatment [34] . Thus, the term osseointegration, when used to rank materials or surfaces, can be more quantitative than the term bioactivity used for bioactive glasses. For the term bioactivity, the fact that the speed at which an HCA layer forms on the surface of a given bioactive glass is often used to convey a more 'bioactive' and therefore potentially better implant material, is perhaps a leap too far since the definition of bioactivity that is accepted depends on a biological response to a material that results in a bond with tissue. Somehow, that bond must be measured if one is to use bioactivity as a quantitative value.
Commercial status of bioactive glass and concluding remarks
Fifty years after the first animal experiment with the original bioactive glass composition (45S), the field of bioactive glasses is robust and has seen significant commercial utility. The main applications of this material for medical devices cleared for market through the various regulatory schemes include particulates for bone regeneration mainly in spine fusion applications, in fibrous forms for use in chronic wound healing as a dressing and as fine particulates in oral care, mainly as an ingredient in toothpaste to treat dentinal hypersensitity. There are also a number of additional forms and uses of these materials currently in clinical studies in humans. It is beyond the scope of this short article to go into the details of these various applications, but the reader is directed to two recent and quite complete reviews of the field and status of bioactive glasses: one published in 2017 by Montazerian and Zanotto, and one published in 2018 by Baino, Hamzehlou and Kargozar [35, 36] . These reviews not only give a more complete picture of the chronology of developments in the field of bioactive glasses, they also trace the commercial development of these materials.
It is safe to say that the process of getting from an idea for a novel or even just improved material to a finished medical device allowed for sale is an arduous one. The path to commercial success of bioactive glasses, which began in 1985 with the first middle ear prosthesis has not been simple, nor straightforward, for many business and regulatory reasons which are well beyond the scope of this article. However, what has always been impressive as one reviews the commercial landscape is that the use of bioactive glass in medical devices has rarely been associated with any significant adverse responses for any given application. Certainly, there have been clinical failures and if not used properly the materials can result in localized adverse events, but as a class of materials these appear to be the most biocompatible materials in the market today. A word of caution is needed, however; safety for materials used in medical devices is determined by the safety of the medical device ultimately used for a given application, or indication for use. Thus, a material that appears to be very safe in early biocompatibility testing might be incorporated into a device that ultimately is determined to be unsafe for use.
The ultimate test of any new biomaterial or application of a biomaterial is in the human clinical performance of the device. This is perhaps the greatest challenge to the advancement of bioactive glasses. Clinical trials are long, difficult to conduct and very expensive to run. In the development of any medical device or drug delivery system, the marketplace often dictates what applications pass the barrier of rising to the level of supporting clinical trials. With a focus on those elements highlighted in this article and the knowledge of surface chemistry, ionic release, implant surface topography, surface charge and how to determine how those affect cells and tissues it should be possible to streamline some of the testing needed to gain access to clinical studies. While the HCA layer formation and the generic use of the term bioactivity has some value as descriptive elements, the field should focus on what has been learned recently about how these other properties of bioactive glasses impact the cellular response and how to harness those into advanced applications.
Bioactive glasses have already received a positive response in the market, and the promise of future applications are much grander in scope and scale than what the current applications are today. The review papers on bioactive glasses cited above go into some detail about tissue engineering applications and scaffolds and different forms and compositions of materials. In 2006, in his article "The story of Bioglass" Hench posits that, "It should be feasible to design a new generation of gene-activating biomaterials tailored for specific patients and disease states." He goes on to state, "Tissue-engineered constructs based on a patient's own cells may be produced that can be used to select an optimal pharmaceutical treatment". Professor Hench always was a visionary in this field and some of what he stated in that section of the article is becoming closer to reality and that is a testament not only to the man, but to the invention he produced that began this journey into what we call bioactive materials.
With the significant advances in the materials sciences and the biological fields these past 15 to 20 years, the vision of being able to create those patient specific solutions and tissue engineered organs is becoming closer to a reality. While serious challenges still remain, the pace of progress has not slowed and this gives one confidence that cell seeded scaffolds will become fully integrated as new, natural tissue. These new visions and possibilities bring new challenges and thus perhaps requires a reset of how one thinks about and describes bioactive materials.
It was over forty years ago that Professor Hench coined the phrase 'bioactive glass' and the term 'bioactivity'. These terms were strictly limited (at the time) to trying to describe features of these materials related to monolithic constructs used to repair bone defects or to be used as structural bone replacement devices. It is a testament to the thought processes that these definitions have remained largely unchanged in the lexicon that biomaterials scientists use today. That said, perhaps it is time to re-think the definition of bioactivity as it relates to this class of materials. Perhaps bioactivity should be more centered on how chemistry, surface charge, topography, ionic release and the local environment control the biological events that lead to the very positive outcomes that we see in many of the research articles published today, and less on the formation of a bond with tissues.
Certainly, the works referenced in this article and in the extensive review articles have highlighted the fact that surface texture, ionic release from bioactive glasses and surface chemistry are critical to the performance of these materials. Perhaps the formation of a hydroxyl carbonate apatite layer is merely an outcome of these properties, rather than a required physical entity that is described as the mechanism of bone-bonding. Trying to decipher all of the biological queues given when cells are exposed to bioactive glasses is incredibly complex and perhaps beyond our ability currently to completely understand and resolve. In his last review manuscript on the history of bioactive glasses, published in the inaugural issue of this journal, Professor Hench laid out a challenge to those working in the field, not to focus on small incremental advancements in the field, but rather to, ". . . strive for unique and innovative approaches at a fundamental molecular biology level to create new bioactive materials. . . " [37] . While the challenge laid out by Professor Hench is certainly a steep one, it is one worthy of pursuit. It might seem a daunting task to live up to that challenge, but 25 years ago the thought of completely cataloguing the human genome was regarded by some as onerous, nearly impossible and yet today it stands as a great achievement and has facilitated many of the advances of the past decade. In "The story of Biolgass" Professor Hench concluded, "But we need to remember that only 35 years ago the concept of a material that would not be rejected by living tissues also seemed unimaginable. Bioglass provides a starting point". That same sentiment holds true today.
